ImmunityBio (IBRX) EBIT Growth (5y) (2019 - 2026)
Powered by 
Analysis
ImmunityBio (IBRX) EBIT Growth (5y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | ImmunityBio | 8.45 Bn | 8.10 Bn | 50.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.41% |
| Mar 31, 2026 | 4.15% |
| Dec 31, 2025 | -15.93% |
| Sep 30, 2025 | 3.32% |
| Jun 30, 2025 | -6.96% |
| Mar 31, 2025 | -11.91% |
| Dec 31, 2024 | -33.92% |
| Sep 30, 2024 | -37.95% |
| Jun 30, 2024 | -41.85% |
| Mar 31, 2024 | -39.02% |
| Dec 31, 2023 | -36.96% |
| Sep 30, 2023 | -27.15% |
| Jun 30, 2023 | -24.66% |
| Mar 31, 2023 | -31.59% |
| Dec 31, 2022 | -27.30% |
| Sep 30, 2022 | -30.02% |
| Jun 30, 2022 | -27.30% |
| Mar 31, 2022 | -30.39% |
| Dec 31, 2021 | -25.82% |
| Sep 30, 2021 | -19.19% |